false
English
Catalog
2025 Hot Topic in Basic & Translational Science: S ...
PP01.19: Real World Safety of Tarlatamab Step-Up D ...
PP01.19: Real World Safety of Tarlatamab Step-Up Dosing in Extensive Stage Small Cell Lung Cancer
Back to course
Pdf Summary
The H. Lee Moffitt Cancer Center conducted a real-world study on the safety of Tarlatamab, a bispecific T-cell engager approved for treating recurrent or relapsed extensive-stage small cell lung cancer (SCLC). This study followed 31 patients from May to November 2024, assessing the incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), focusing on grades, timing, and rates of prolonged hospitalization or readmission.<br /><br />Tarlatamab treatment in the initial patient cohort resulted in severe adverse events, with three instances of CRS/ICANS leading to mortality or hospice care. As a response, prophylactic Tocilizumab (pToci) was implemented to moderate high-risk patients, characterized by factors like advanced age, comorbidities, and elevated inflammatory markers. <br /><br />Outcomes showed that CRS and ICANS occurred most frequently after the initial C1D1 dose, with 55.5% experiencing CRS and 22.2% experiencing ICANS at varying grades. Notably, the timing of symptom onset was around 11 hours for CRS and 12 hours for ICANS. For patients receiving prophylactic Tocilizumab, only one recorded a Grade 2 ICANS during C1D8, and no CRS events were observed throughout the cycle.<br /><br />In summary, the prophylactic use of Tocilizumab showed potential in reducing CRS and ICANS risks, particularly in patients with identifiable high-risk profiles. The study highlights the necessity for vigilant monitoring and potential prophylactic interventions in managing Tarlatamab treatment outcomes in SCLC.
Asset Subtitle
Sonam Puri
Keywords
Tarlatamab
bispecific T-cell engager
small cell lung cancer
cytokine release syndrome
immune effector cell-associated neurotoxicity syndrome
prophylactic Tocilizumab
adverse events
real-world study
high-risk patients
treatment outcomes
×
Please select your language
1
English
5
普通话
11
Dutch